How to buy Kiromic Biopharma stock (Kiromic Biopharma)

Kiromic Biopharma is a biotechnology business based in the US. Kiromic Biopharma shares (KRBP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.92 – a decrease of 3.16% over the previous week. Kiromic Biopharma employs 35 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Kiromic Biopharma Inc stock

Buy Kiromic Biopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Kiromic Biopharma stock price (NASDAQ: KRBP)

Use our graph to track the performance of KRBP stocks over time.

Kiromic Biopharma shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.92
52-week range	$0.29 - $3.78
50-day moving average more info button	$1.03
200-day moving average more info button	$1.97
Wall St. target price	N/A
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-6.22

Is it a good time to buy Kiromic Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kiromic Biopharma price performance over time

Historical closes compared with the close of $0.92 from 2024-12-20

1 week (2024-12-13)	-3.16%
1 month (2024-11-22)	-15.60%
3 months (2024-09-20)	-35.21%
6 months (2024-06-21)	-63.35%

1 year (2023-12-22)	219.44%
2 years (2022-12-22)	-82.11%
3 years (2021-12-22)	50.4
5 years (2019-12-18)	N/A

Kiromic Biopharma financials

Gross profit TTM	$0
Return on assets TTM	-119.42%
Return on equity TTM	-1129.81%
Profit margin	0%
Book value	$-6.01
Market Capitalization more info button	$1.7 million

TTM: trailing 12 months

Kiromic Biopharma share dividends

We're not expecting Kiromic Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

• Bio-Techne (TECH.US) (0.45% forward annual dividend yield)

Have Kiromic Biopharma's shares ever split?

Kiromic Biopharma's shares were split on a 1:30 basis on 12 March 2023 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kiromic Biopharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Kiromic Biopharma shares which in turn could have impacted Kiromic Biopharma's share price.

Kiromic Biopharma share price volatility

Over the last 12 months, Kiromic Biopharma's shares have ranged in value from as little as $0.288 up to $3.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiromic Biopharma's is 1.979. This would suggest that Kiromic Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Kiromic Biopharma's beta into context you can compare it against those of similar companies.

• BeiGene (BGNE.US): 0.63
• BioNTech (BNTX.US): 0.259
• Bio-Techne (TECH.US): 1.278
• XBiotech (XBIT.US): 1.413

Kiromic Biopharma overview

Kiromic BioPharma, Inc. , a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S. R. L. The company was formerly known as Kiromic, Inc.

Frequently asked questions

What percentage of Kiromic Biopharma is owned by insiders?
Currently 27.087% of Kiromic Biopharma shares are held by insiders. How many people work for Kiromic Biopharma?
Latest data suggests 35 work at Kiromic Biopharma. When does the fiscal year end for Kiromic Biopharma?
Kiromic Biopharma's fiscal year ends in December. Where is Kiromic Biopharma based?
Kiromic Biopharma's address is: 7707 Fannin Street, Houston, TX, United States, 77054 What is Kiromic Biopharma's ISIN number?
Kiromic Biopharma's international securities identification number is: US4976341051